Use of the epidermal growth factor receptor (EGFR) inhibitor cetuximab with chemoradiation did not improve overall survival (OS) in patients with esophageal carcinoma compared with chemoradiation alone, according to the results of the phase III RTOG 0436 trial.
http://www.cancernetwork.com/esophageal-cancer/adding-cetuximab-esophageal-cancer-fails-improve-survival
Adding Cetuximab in Esophageal Cancer Fails to Improve Survival